Sales & Marketing News | pharmaphorum

News

Elizabeth Holmes heading for prison as appeal fails

Disgraced former biotech chief Elizabeth Holmes will start an 11-year prison sentence at the end of this month, after a federal judge denied her request to remain free whi

News

FDA advisors will look at full Leqembi approval in June

The FDA has convened a meeting of an advisory committee in June to consider the bid by Eisai and Biogen to convert their accelerated approval of Alzheimer’s disease therap

News

GSK told to pay higher royalties to AZ on Zejula sales

A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito

News

Pressure raises on Illumina as FTC orders it to shed Grail

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition an

News

J&J raises talc offer to $9bn with new insolvency bid

Johnson & Johnson has made an offer of nearly $9 billion to try to resolve tens of thousands of lawsuits it faces in the US that claim its talc products cause cancer.&

News

Okyo Pharma abandons UK listing in favour of Nasdaq

Okyo Pharma has decided to delist its shares from the London Stock Exchange and list them on the Nasdaq in New York, blaming “negligible” trading that doesn’t justify the

Elizabeth Holmes heading for prison as appeal fails

FDA advisors will look at full Leqembi approval in June

GSK told to pay higher royalties to AZ on Zejula sales

Pressure raises on Illumina as FTC orders it to shed Grail

J&J raises talc offer to $9bn with new insolvency bid

Okyo Pharma abandons UK listing in favour of Nasdaq

Pfizer cues up vitiligo filing for Litfulo after phase 3 win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks